Reich, G;Cornely, OA;Sandherr, M;Kubin, T;Krause, S;Einsele, H;Thiel, E;Bellaire, T;Dörken, B;Maschmeyer, G
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.
Br J Haematol
2005
130
2
265-70

Keller, U;Nilsson, JA;Maclean, KH;Old, JB;Cleveland, JL
Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
Oncogene
2005
24
41
6231-40

Nilsson, JA;Keller, UB;Baudino, TA;Yang, C;Norton, S;Old, JA;Nilsson, LM;Neale, G;Kramer, DL;Porter, CW;Cleveland, JL
Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Cancer Cell
2005
7
5
433-44

Schlenk, RF;Germing, U;Hartmann, F;Glasmacher, A;Fischer, JT;Fuentes, FDY;Götze, K;Pralle, H;Nerl, C;Salwender, H;Grimminger, W;Petzer, A;Hensel, M;Benner, A;Zick, L;Döhner, K;Frohling, S;Döhner, H
High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
Leukemia
2005
19
6
978-983

Jörg, A;Grubert, T;Grimm, T;Guenzi, E;Naschberger, E;Samson, E;Oostendorp, R;Keller, U;Stürzl, M
Maternal HIV type 1 infection suppresses MMP-1 expression in endothelial cells of uninfected newborns: nonviral vertical transmission of HIV type 1-related effects.
AIDS Res Hum Retroviruses
2005
21
11
940-4

Rondeau, G;McClelland, M;Nguyen, T;Risques, R;Wang, Y;Judex, M;Cho, AH;Welsh, J
Enhanced microarray performance using low complexity representations of the transcriptome.
Nucleic Acids Res
2005
33
11
e100

Judex, MO;Mueller, BM
Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.
Am J Pathol
2005
166
3
645-7

Gilfillan, S;Stelzer, G;Piaia, E;Hofmann, MG;Meisterernst, M
Efficient binding of NC2.TATA-binding protein to DNA in the absence of TATA.
J Biol Chem
2005
280
7
6222-30

Oostendorp, RA;Harvey, K;Dzierzak, EA
Generation of murine stromal cell lines: models for the microenvironment of the embryonic mouse aorta-gonads-mesonephros region.
Methods Mol Biol
2005
290
163-72

Seufferlein, T;Dittrich, C;Riemann, J;Woell, E;Herrmann, T;Lordick, F;Arnold, D;Olchowka, K;Hoehler, T;Schmoll, HJ
A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor recepto
J Clin Oncol
2005
23
16
281S-281S